NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where they present peptides to T cells, which gives them a key role in the development of T-cell immune responses. MHC molecules come in two main variants: MHC Class I (MHC-I) and MHC Class II (MHC-II). MHC-I predominantly present peptides derived from intracellular proteins, whereas MHC-II predominantly presents peptides from extracellular proteins. In both cases, the binding between MHC and antigenic peptides is the most selective step in the antigen presentation pathway. Therefore, the prediction of peptide binding to MHC is a powerful utility to predict the possible specificity of a T-cell immune response. Commonly MHC binding prediction tools are trained on binding affinity or mass spectrometry-eluted ligands. Recent studies have however demonstrated how the integration of both data types can boost predictive performances. Inspired by this, we here present NetMHCpan-4.1 and NetMHCIIpan-4.0, two web servers created to predict binding between peptides and MHC-I and MHC-II, respectively. Both methods exploit tailored machine learning strategies to integrate different training data types, resulting in state-of-the-art performance and outperforming their competitors. The servers are available at http://www.cbs.dtu.dk/services/NetMHCpan-4.1/ and http://www.cbs.dtu.dk/services/NetMHCIIpan-4.0/.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these tools, NetMHCpan stands out in predicting the binding affinity between peptides and MHC-I/II, respectively [139].”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [139]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Self-citationImproved methods for predicting peptide binding affinity to MHC class II molecules
Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan, Z., Sette, A., Peters, B., & Nielsen, M. (2018) · Immunology · doi:10.1111/imm.12889 · Cited by 794
Self-citationAbelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.007 · Cited by 617
Nielsen, M., & Andreatta, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0288-x · Cited by 517
Self-citationSarkizova, S., Klaeger, S., Le, P. M., Li, L. W., Oliveira, G., Keshishian, H., Hartigan, C. R., Zhang, W., Braun, D. A., Ligon, K. L., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0322-9 · Cited by 499
Reynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W. H., Peters, B., & Nielsen, M. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00874 · Cited by 445
Self-citationMHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O'Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 409
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
Racle, J., Michaux, J., Rockinger, G. A., Arnaud, M., Bobisse, S., Chong, C., Guillaume, P., Coukos, G., Harari, A., Jandus, C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0289-6 · Cited by 289
Karosiene, E., Rasmussen, M., Blicher, T., Lund, O., Buus, S., & Nielsen, M. (2013) · Immunogenetics · doi:10.1007/s00251-013-0720-y · Cited by 272
Self-citation
Research works printed but not linked: 1
- O’Donnell T.J., Rubinsteyn A., Bonsack M., Riemer A.B., Laserson U., Hammerbacher J. 2020; MHCFlurry https://github.com/openvax/mhcflurry. 29960884
Cited by
Items 101–200 of 1,014
Cheng, J., Bendjama, K., Rittner, K., & Malone, B. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab422 · Cited by 84
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Pang, Z., Lu, M., Zhang, Y., Gao, Y., Bai, J. J., Gu, J., Xie, L., & Wu, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00534-0 · Cited by 83
Foss, S., Sakya, S. A., Aguinagalde, L., Lustig, M., Shaughnessy, J., Cruz, A. R., Scheepmaker, L., Mathiesen, L., Ruso-Julve, F., Anthi, A. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46321-9 · Cited by 82
Targeting of intracellular oncoproteins with peptide-centric CARs
Yarmarkovich, M., Marshall, Q. F., Warrington, J. M., Premaratne, R., Farrel, A., Groff, D., Li, W., di Marco, M., Runbeck, E., Truong, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06706-0 · Cited by 82
Mahapatra, S. R., Sahoo, S., Dehury, B., Raina, V., Patro, S., Misra, N., & Suar, M. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1811091 · Cited by 82
Bauer, J., Köhler, N., Maringer, Y., Bucher, P., Bilich, T., Zwick, M., Dicks, S., Nelde, A., Dubbelaar, M. L., Scheid, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33746-3 · Cited by 82
Cohen, K. W., Rosa, S. C. D., Fulp, W. J., deCamp, A. C., Fiore-Gartland, A. J., Mahoney, C. R., Furth, S., Donahue, J. G., Whaley, R. E., Ballweber-Fleming, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf3309 · Cited by 82
Artificial intelligence in lung cancer: current applications, future perspectives, and challenges
Huang, D., Li, Z., Jiang, T., Yang, C., & Li, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1486310 · Cited by 82
Zolg, D. P., Gessulat, S., Paschke, C., Graber, M., Rathke‐Kuhnert, M., Seefried, F., Fitzemeier, K., Berg, F., López‐Ferrer, D., Horn, D. M., et al. (2021) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9128 · Cited by 81
Schmidt, J., Chiffelle, J., Perez, M. A. S., Magnin, M., Bobisse, S., Arnaud, M., Genolet, R., Cesbron, J., Barras, D., Rodrigo, B. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38946-z · Cited by 84
Liu, G., Carter, B., Bricken, T., Jain, S., Viard, M., Carrington, M. N., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.06.009 · Cited by 80
Neoantigen cancer vaccines: a new star on the horizon
Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 79
Autoreactive T cells target peripheral nerves in Guillain–Barré syndrome
Súkeníková, L., Mallone, A., Schreiner, B., Ripellino, P., Nilsson, J., Stoffel, M., Ulbrich, S. E., Sallusto, F., & Latorre, D. (2024) · Nature · doi:10.1038/s41586-023-06916-6 · Cited by 79
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation
Borden, E. S., Buetow, K. H., Wilson, M. A., & Hastings, K. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836821 · Cited by 78
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives
Sohail, M. S., Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.007 · Cited by 78
Wang, W., Yuan, T., Ma, L., Zhu, Y., Bao, J., Zhao, X., Zhao, Y., Zong, Y., Zhang, Y., Yang, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105810 · Cited by 78
Mahapatra, S. R., Dey, J., Jaiswal, A., Roy, R., Misra, N., & Suar, M. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113325 · Cited by 78
De novo-designed pMHC binders facilitate T cell–mediated cytotoxicity toward cancer cells
Johansen, K. H., Wolff, D. S., Scapolo, B., Fernández-Quintero, M. L., Risager Christensen, C., Loeffler, J. R., Rivera-de-Torre, E., Overath, M. D., Kjærgaard Munk, K., Morell, O., et al. (2025) · Science · doi:10.1126/science.adv0422 · Cited by 77
Quadeer, A. A., Ahmed, S. F., & McKay, M. R. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100312 · Cited by 76
Parry, E. M., Lemvigh, C. K., Deng, S., Dangle, N. J., Ruthen, N. G., Knisbacher, B. A., Broséus, J., Hergalant, S., Guièze, R., Li, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.013 · Cited by 77
Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics
Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., Pathak, D., Chanchal, D. K., & Kant, L. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010275850240102105033 · Cited by 76
Engineered cell entry links receptor biology with single-cell genomics
Yu, B., Shi, Q., Belk, J. A., Yost, K. E., Parker, K. R., Li, R., Liu, B. B., Huang, H., Lingwood, D., Greenleaf, W. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.016 · Cited by 75
Design of a multi-epitope vaccine candidate against Brucella melitensis
Li, M., Zhu, Y., Niu, C., Xie, X., Haimiti, G., Guo, W., Yu, M., Chen, Z., Ding, J., & Zhang, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-14427-z · Cited by 75
Molecular basis of MHC I quality control in the peptide loading complex
Domnick, A., Winter, C., Sušac, L., Hennecke, L., Hensen, M., Zitzmann, N., Trowitzsch, S., Thomas, C., & Tampé, R. (2022) · Nature Communications · doi:10.1038/s41467-022-32384-z · Cited by 75
Mahmoodi, S., Amirzakaria, J. Z., & Ghasemian, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285177 · Cited by 75
Jensen, M. F., & Nielsen, M. (2024) · eLife · doi:10.7554/elife.93934.3 · Cited by 75
Self-citationMei, S., Li, F., Xiang, D., Ayala, R., Faridi, P., Webb, G. I., Illing, P. T., Rossjohn, J., Akutsu, T., Croft, N. P., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa415 · Cited by 74
Naito, T., & Okada, Y. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00901-9 · Cited by 75
Accurate modeling of peptide-MHC structures with AlphaFold
Mikhaylov, V., Brambley, C. A., Keller, G. L. J., Arbuiso, A. G., Weiss, L. I., Baker, B. M., & Levine, A. J. (2024) · Structure · doi:10.1016/j.str.2023.11.011 · Cited by 72
CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
Shi, Z., Shen, J., Qiu, J., Zhao, Q., Hua, K., & Wang, H. (2021) · Theranostics · doi:10.7150/thno.59056 · Cited by 72
Accurate modeling of peptide-MHC structures with AlphaFold
Mikhaylov, V., & Levine, A. J. (2023) · doi:10.1101/2023.03.06.531396 · Cited by 72
The combination of artificial intelligence and systems biology for intelligent vaccine design
Russo, G., Reche, P., Pennisi, M., & Pappalardo, F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791076 · Cited by 71
Chatterjee, R., Sahoo, P., Mahapatra, S. R., Dey, J., Ghosh, M., Kushwaha, G. S., Misra, N., Suar, M., Raina, V., & Son, Y. (2021) · Vaccines · doi:10.3390/vaccines9091038 · Cited by 69
Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides
Ferreira, H. J., Stevenson, B. J., Pak, H., Yu, F., Oliveira, J., Huber, F., Taillandier-Coindard, M., Michaux, J., Altimiras, E. R., Kraemer, A. I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46408-3 · Cited by 68
Strandgaard, T., Nordentoft, I., Birkenkamp‐Demtröder, K., Salminen, L., Prip, F., Rasmussen, J., Andreasen, T. G., Lindskrog, S. V., Christensen, E., Lamy, P., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.07.014 · Cited by 67
Ahmad, S., Demneh, F. M., Rehman, B., Almanaa, T. N., Akhtar, N., Pazoki–Toroudi, H., Shojaeian, A., Ghatrehsamani, M., & Sanami, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131517 · Cited by 67
Camarena, M. E., Theunissen, P., Ruiz, M., Ruiz‐Orera, J., Calvo-Serra, B., Castelo, R., Castro, C., Sarobe, P., Fortes, P., Perera‐Bel, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn3628 · Cited by 68
Computational epitope-based vaccine design with bioinformatics approach; a review
Basmenj, E. R., Pajhouh, S. R., Ebrahimi-Fallah, A., Naijian, R., Rahimi, E., Atighy, H., Ghiabi, S., & Ghiabi, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41714 · Cited by 67
Becker, J. P., & Riemer, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883989 · Cited by 66
epiTCR: a highly sensitive predictor for TCR–peptide binding
Pham, M.-D. N., Nguyen, T.-N., Tran, L. S., Nguyen, Q.-T. B., Nguyen, T.-P. H., Pham, T. M. Q., Nguyen, H.-N., Giang, H., Phan, M.-D., & Nguyen, V. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad284 · Cited by 65
Kaushik, V., Sunil Krishnan, G., Gupta, L. R., Kalra, U., Shaikh, A. R., Cavallo, L., & Chawla, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865180 · Cited by 65
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19
Stanevich, O. V., Alekseeva, E. I., Sergeeva, M. V., Fadeev, A. V., Komissarova, K., Ivanova, A. A., Simakova, T., Vasilyev, K., Shurygina, A.-P. S., Stukova, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-34033-x · Cited by 65
In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis
Andongma, B. T., Huang, Y., Chen, F., Tang, Q., Yang, M., Chou, S., Li, X., & He, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.019 · Cited by 65
Li, T., Li, Y., Zhu, X., He, Y., Wu, Y., Ying, T., & Xie, Z. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.007 · Cited by 65
Stražar, M., Park, J., Abelin, J. G., Taylor, H. B., Pedersen, T. K., Plichta, D. R., Brown, E., Eraslan, B., Hung, Y.-M., Ortiz, K., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.009 · Cited by 65
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity
Lee, E., Sandgren, K. J., Duette, G., Stylianou, V. V., Khanna, R., Eden, J., Blyth, E., Gottlieb, D. J., Cunningham, A. L., & Palmer, S. (2020) · Journal of Virology · doi:10.1128/jvi.02002-20 · Cited by 65
Li, W., Huang, L., Li, Y., Feng, Y.-Y., Zhang, Z., Xu, Z., Chen, M., & Cheng, Y. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.130357 · Cited by 65
Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery
Pogorelyy, M. V., Rosati, E., Minervina, A. A., Mettelman, R. C., Scheffold, A., Franke, A., Bächer, P., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100697 · Cited by 64
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 64
Song, K. J., Choi, S., Kim, K., Hwang, H. S., Chang, E., Park, J. S., Shim, S. B., Choi, S., Heo, Y. J., An, W. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54434-4 · Cited by 64
Zinsli, L. V., Stierlin, N., Loessner, M. J., & Schmelcher, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.024 · Cited by 63
Rapid assessment of T-cell receptor specificity of the immune repertoire
Lin, X., George, J. T., Schafer, N. P., Chau, K. N., Birnbaum, M. E., Clementi, C., Onuchic, J. N., & Levine, H. (2021) · Nature Computational Science · doi:10.1038/s43588-021-00076-1 · Cited by 63
Akhtar, N., Kaushik, V., Grewal, R. K., Wani, A. K., Suwattanasophon, C., Choowongkomon, K., Oliva, R., Shaikh, A. R., Cavallo, L., & Chawla, M. (2022) · Viruses · doi:10.3390/v14112374 · Cited by 63
Ratovomanana, T., Nicolle, R., Cohen, R., Diehl, A., Siret, A., Letourneur, Q., Buhard, O., Perrier, A., Guillerm, E., Coulet, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.010 · Cited by 63
Feng, Z., Chen, J., Hai, Y., Pang, X., Zheng, K., Xie, C., Zhang, X., Li, S., Zhang, C., Liu, K., et al. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00901-y · Cited by 63
Rational engineering of minimally immunogenic nucleases for gene therapy
Raghavan, R. S., Friedrich, M., King, C., Vo, C.-D.-T., Strebinger, D., Lash, B., Kilian, M., Platten, M., Macrae, R. K., Song, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55522-1 · Cited by 63
Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond
Pagliuca, S., Gurnari, C., Rubio, M., Visconte, V., & Lenz, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944872 · Cited by 62
TScan-II: A genome-scale platform for the de novo identification of CD4+ T cell epitopes
Dezfulian, M. H., Kula, T., Pranzatelli, T. J. F., Kamitaki, N., Meng, Q., Khatri, B., Pérez, P., Xu, Q., Chang, A., Kohlgruber, A. C., et al. (2023) · Cell · doi:10.1016/j.cell.2023.10.024 · Cited by 62
Main Strategies for the Identification of Neoantigens
Gopanenko, A. V., Kosobokova, E. N., & Kosorukov, V. S. (2020) · Cancers · doi:10.3390/cancers12102879 · Cited by 63
Kaushik, V., Jain, P., Akhtar, N., Joshi, A., Gupta, L. R., Grewal, R. K., Oliva, R., Shaikh, A. R., Cavallo, L., & Chawla, M. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00130 · Cited by 61
A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens
Minati, R., Perreault, C., & Thibault, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583287 · Cited by 61
Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 60
Zhang, Y., Zhu, G., Li, K., Li, F., Huang, L., Duan, M., & Zhou, F. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac173 · Cited by 60
Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection
Li, J., Ju, Y., Jiang, M., Li, S., & Yang, X.-Y. (2025) · Vaccines · doi:10.3390/vaccines13030248 · Cited by 60
An Intravascular Magnetic Catheter Enables the Retrieval of Nanoagents from the Bloodstream
Iacovacci, V., Ricotti, L., Sinibaldi, E., Signore, G., Vistoli, F., & Menciassi, A. (2018) · Advanced Science · doi:10.1002/advs.201800807 · Cited by 60
Mahajan, S., Kode, V., Bhojak, K., Coral, K., Lee, K. M., Manoharan, M., Ramesh, A., Sudheendra, H., Srivastava, A., Sathian, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92521-4 · Cited by 61
Bruno, P. M., Timms, R. T., Abdelfattah, N. S., Leng, Y., Lelis, F., Wesemann, D. R., Yu, X. G., & Elledge, S. J. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01566-x · Cited by 59
Zhang, N., Cheng, X., Zhu, Y., Mo, O., Yu, H., Zhu, L., Zhang, J., Kuang, L., Gao, Y., Cao, R., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2378-x · Cited by 59
Elfatimi, E., Lekbach, Y., Prakash, S., & BenMohamed, L. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1620572 · Cited by 59
Local adaptation in populations of Mycobacterium tuberculosis endemic to the Indian Ocean Rim
Menardo, F., Rutaihwa, L. K., Zwyer, M., Borrell, S., Comas, I., Conceição, E. C., Coscollá, M., Cox, H. S., Joloba, M. L., Dou, H.-Y., et al. (2021) · F1000Research · doi:10.12688/f1000research.28318.2 · Cited by 60
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis
Muñiz‐Castrillo, S., Hedou, J. J., Ambati, A., Jones, D., Vogrig, A., Pinto, A., Bénaiteau, M., de Broucker, T., Fechtenbaum, L., Labauge, P. M., et al. (2021) · Brain · doi:10.1093/brain/awab153 · Cited by 58
Omoniyi, A. A., Adebisi, S. S., Musa, S. A., Nzalak, J. O., Bauchi, Z. M., Bako, K. W., Olatomide, O. D., Zachariah, R., & Nyengaard, J. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-12651-1 · Cited by 57
Mahapatra, S. R., Dey, J., Raj, T. K., Misra, N., & Suar, M. (2023) · Pathogens · doi:10.3390/pathogens12030376 · Cited by 57
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification
Gravel, N. H., Nelde, A., Bauer, J., Mühlenbruch, L., Schroeder, S. M., Neidert, M. C., Scheid, J., Lemke, S., Dubbelaar, M. L., Wacker, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42692-7 · Cited by 57
Apavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J., Hardy, M., Vincent, K., Brochu, S., Laverdure, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00979-2 · Cited by 57
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma
Blass, E., Keskin, D. B., Tu, C. R., Forman, C., Vanasse, A. P., Sax, H. E., Shim, B., Chea, V. A., Kim, N., Carulli, I. P., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.019 · Cited by 57
Nilsson, J. B., Greenbaum, J., Peters, B., & Nielsen, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616113 · Cited by 57
Self-citationDragon, A. C., Zimmermann, K., Nerreter, T., Sandfort, D., Lahrberg, J., Klöß, S., Kloth, C., Mangare, C., Bonifacius, A., Tischer‐Zimmermann, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000736 · Cited by 57
Nilsson, J. B., Kaabinejadian, S., Yari, H., Peters, B., Barra, C., Gragert, L. A., Hildebrand, W. H., & Nielsen, M. (2023) · Communications Biology · doi:10.1038/s42003-023-04749-7 · Cited by 57
Self-citationProspects for the computational humanization of antibodies and nanobodies
Gordon, G. L., Raybould, M. I. J., Wong, A., & Deane, C. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399438 · Cited by 56
Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy
Bulashevska, A., Nacsa, Z., Lang, F., Braun, M., Machyna, M., Diken, M., Childs, L. H., & König, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1394003 · Cited by 56
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
Puttick, C., Jones, T. P., Leung, M. M., Gálvez‐Cancino, F., Liu, J., Varas‐Godoy, M., Rowan, A., Pich, O., Martínez‐Ruiz, C., Bentham, R. B., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01883-8 · Cited by 56
Lee, M. N., & Meyerson, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4001 · Cited by 56
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Liang, J., & Zhao, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0004 · Cited by 56
Accelerating therapeutic protein design with computational approaches toward the clinical stage
Chen, Z., Wang, X., Chen, X., Huang, J., Wang, C., Wang, J., & Wang, Z. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.04.027 · Cited by 55
Zhao, Y., Jiang, H., Yu, J., Wang, L., & Du, J. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202304692 · Cited by 55
Huisman, B. D., Guan, N., Rückert, T., Garner, L. I., Singh, N. K., McMichael, A. J., Gillespie, G. M. A., Romagnani, C., & Birnbaum, M. E. (2023) · Nature Communications · doi:10.1038/s41467-023-40220-1 · Cited by 57
Structure-based prediction of T cell receptor recognition of unseen epitopes using TCRen
Карнаухов, В. К., Shcherbinin, D. S., Chugunov, A. O., Chudakov, D. M., Efremov, R. G., Zvyagin, I. V., & Shugay, M. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00653-0 · Cited by 55
Cai, Y., Gong, M., Zeng, M., Leng, F., Lv, D., Guo, J., Wang, H., Li, Y., Lin, Q., Jing, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv6445 · Cited by 55
Lu, Y., Huang, W., Li, Y., Xu, Y., Wei, Q., Sha, C., & Guo, P. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01159-2 · Cited by 56
Computational cancer neoantigen prediction: current status and recent advances
Fotakis, G., Trajanoski, Z., & Rieder, D. (2021) · Immuno-Oncology and Technology · doi:10.1016/j.iotech.2021.100052 · Cited by 54
Leddy, O. K., White, F. M., & Bryson, B. D. (2023) · eLife · doi:10.7554/elife.84070 · Cited by 54
Andreu‐Sánchez, S., Bourgonje, A. R., Vogl, T. J., Kurilshikov, A., Leviatan, S., Ruiz-Moreno, A. J., Hu, S., Sinha, T., Vila, A. V., Klompus, S., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.04.003 · Cited by 54
Circular RNA as a source of neoantigens for cancer vaccines
Ren, Y., Manoharan, T., Liu, B., Cheng, C. Z. M., Siew, B. E., Cheong, W., Lee, K. Y., Tan, I. J.-W., Lieske, B., Tan, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008402 · Cited by 54
Genetic variability in COVID-19-related genes in the Brazilian population
Secolin, R., de Araujo, T. K., Gonsales, M. C., Rocha, C. S., Naslavsky, M. S., Marco, L. A. D., Bicalho, M. A. C., Vazquez, V. D. L., Zatz, M., Silva, W. A., et al. (2021) · Human Genome Variation · doi:10.1038/s41439-021-00146-w · Cited by 54
Liu, G., Carter, B., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.010 · Cited by 53
BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity
Eggenhuizen, P. J., Ng, B. H., Chang, J., Fell, A. L., Cheong, R. M. Y., Wong, W. Y., Gan, P., Holdsworth, S. R., & Ooi, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692729 · Cited by 53
Alban, T. J., Riaz, N., Parthasarathy, P. B., Makarov, V., Kendall, S. M., Yoo, S., Shah, R., Weinhold, N., Srivastava, R. M., Ma, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03240-y · Cited by 53
diaTracer enables spectrum-centric analysis of diaPASEF proteomics data
Li, K., Teo, G. C., Yang, K., Yu, F., & Nesvizhskii, A. I. (2025) · Nature Communications · doi:10.1038/s41467-024-55448-8 · Cited by 53
Metadata
- Authors
- Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M.
- Affiliations
- Technical University of Denmark (DK)
- National University of General San Martín (AR)
- La Jolla Institute for Immunology (US)
- Corresponding author
- Nielsen, Morten
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-14
- Volume
- 48
- Issue
- W1
- Pages
- W449-W454
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC7319546
- OpenAlex
- W3024570138
- Cited by
- 2,361
- References
- 26
- Citations by year
- 2026: 493 · 2025: 550 · 2024: 459 · 2023: 345 · 2022: 250 · 2021: 216 · 2020: 47
- FWCI
- 69.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (75N93019C00001)
- EIT Health (19638)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
- Keywords
- MHC-peptide binding prediction, MHC class I, MHC class II, antigen presentation, NetMHCpan, machine learning, web server, T cell response
- MeSH terms
- Machine Learning, Histocompatibility Antigens Class II, Ligands, Peptides, Software, Histocompatibility Antigens Class I, Antigen Presentation, Amino Acid Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.